Price T Rowe Associates Inc. MD Boosts Stock Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)

Price T Rowe Associates Inc. MD raised its position in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 10,982.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,268,509 shares of the company's stock after buying an additional 1,257,063 shares during the quarter. Price T Rowe Associates Inc. MD owned about 2.41% of Kodiak Sciences worth $12,622,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. PNC Financial Services Group Inc. grew its stake in shares of Kodiak Sciences by 1,501.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock worth $32,000 after purchasing an additional 2,988 shares during the period. US Bancorp DE purchased a new position in Kodiak Sciences during the fourth quarter worth approximately $40,000. Headlands Technologies LLC purchased a new position in shares of Kodiak Sciences during the 4th quarter valued at approximately $90,000. JPMorgan Chase & Co. lifted its holdings in Kodiak Sciences by 220.9% during the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company's stock valued at $117,000 after purchasing an additional 30,735 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Kodiak Sciences in the fourth quarter valued at about $118,000. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences Price Performance

Shares of KOD stock traded down $1.11 during trading on Tuesday, reaching $3.81. The company's stock had a trading volume of 954,081 shares, compared to its average volume of 348,061. The company has a market capitalization of $200.99 million, a price-to-earnings ratio of -1.04 and a beta of 2.42. Kodiak Sciences Inc. has a 1-year low of $1.92 and a 1-year high of $11.60. The stock's 50-day moving average price is $3.28 and its 200 day moving average price is $5.50.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.06. On average, sell-side analysts anticipate that Kodiak Sciences Inc. will post -3.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "neutral" rating and set a $3.00 target price on shares of Kodiak Sciences in a report on Monday, March 31st.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.